Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil - Hsu, C-Y; Shen, Y-C; Yu, C-W (J Hepatol, 2011)
, et al.